Teva

Mega deal: Teva acquires Emalex for approximately $900 million

The Israeli pharmaceutical giant is accelerating its growth strategy and adding to its portfolio a groundbreaking treatment for Tourette syndrome in children.

The logistics center of Teva Pharmaceutical Industries in Shoham
Noam Zilbershtain, senior vice president and general manager, HP Indigo; Adi Soffer Teeni, CEO of Meta Israel, vice president and member of the EMEA leadership team; and Karin Mayer Rubinstein, CEO and president of IATI.

IATI CEOs Forum meets in Kiryat Gat to discuss multinational industry resilience

Amalia Adler-Waxman, Iris Gilboa, Yael Ashman, receiving the Keshet award for promoting gender equality in corporations, presented by Ilan Flato and Anat Pilzer-Somech at the Tel Aviv Stock Exchange.

Teva honored for gender equality as women reach 43% of senior management in Israel

Logo of Teva Pharmaceutical

Teva collaborates on skin disease treatment, releases targets


Teva donates potential coronavirus treatment to hospitals across the US

Hydroxychloroquine sulfate tablets are used against malaria, lupus erythematosus and rheumatoid arthritis but could be effective against COVID-19.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

After turbulent years, Teva CEO Schultz forecasts stability

Teva completed its two-year major restructuring plan in 2019, reducing its cost base by over $3 billion and net debt by more than $9b.

Teva CEO Kåre Schultz at the Tel Aviv Stock Exchange, February 19, 2020

Teva's first ever National Forum for Bio-Innovators gathers in Tel Aviv

Researcher Hila Flayev has for years been conducting research on computational models of the coronavirus structure and interactions it can create.

Teva's first ever National Forum for Bio-Innovators gathers in Tel Aviv

Teva Naot launches store in Vancouver, Canada

In 2019, Teva Naot sold about 100,000 pairs of shoes in its stores and to retailers, and through the website in the Canadian market.

FROM RIGHT TO LEFT: Teva Naot CEO Michael Iluz, spokesmodel Dana Grotsky and owner Steve Lax

Teva’s proposed settlement could cost drugmaker pennies on the dollar

Israel-based Teva is looking to reach a nationwide settlement over its role in selling opioid painkillers, together with drugmaker Johnson & Johnson and the three largest U.S. drug distributors.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

Teva shares surge amid hopes of $23 billion opioid claims settlement

Teva stocks also closed up 8.67% on the New York Stock Exchange on Monday amid growing optimism.

Pharmacist Jim Pearce fills a Suboxone prescription at Boston Healthcare for the Homeless Program in Boston

Opioid settlement talks fail with Teva, landmark trial expected Monday

After nearly 11 hours of negotiations, Pennsylvania Attorney General Josh Shapiro told reporters it was “profoundly disappointing” that local governments would not go along with a settlement.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem

Teva proposes $15 billion deal to settle opioid claims

The proposed settlement comes only days ahead of a landmark federal trial in Cleveland, Ohio, against the company and five drug distributors.

The CEO of Teva Pharmaceutical Industries Kare Schultz speaks during a news conference to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019

Teva joins medical cannabis market with Israel distribution deal

Under the agreement announced Friday, S.L.E. will distribute Canndoc's GMP-approved products to clients in Israel, including hospitals, health maintenance organizations (HMOs) and all pharmacies.

Employee tends to medical cannabis plants at Pharmocann, an Israeli medical cannabis company in northern Israel

Teva launches generic version of EpiPen for young children

The drugmaker has been struggling with falling prices of generics and faces lawsuits that allege it helped fuel the U.S. opioid addiction epidemic.

A building belonging to generic drug producer Teva, Israel's largest company with a market value of about $57 billion, is seen in Jerusalem